Alnylam initiated at UBS
Alnylam initiated with a Neutral at UBS. UBS analyst Navin Jacob started Alnylam Pharmaceuticals with a Neutral rating and $87 price target. Near-term uncertainty suggests the shares are fairly valued, the analyst contends.https://thefly.com/landingPageNews.php?id=2852055
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.